Chemoprophylaxis of neonatal fungal infections in very low birthweight infants: efficacy and safety of fluconazole and nystatin

School of Paediatrics and Child Health, University of Western Australia Department of Paediatric and Adolescent Medicine and PathWest Laboratory Medicine, Princess Margaret Hospital for Children, Subiaco, Western Australia George Institute for Global Health, University of Sydney Children's Hospital at Westmead, Westmead University of Sydney, Sydney, New South Wales, Australia.
Journal of Paediatrics and Child Health (Impact Factor: 1.19). 09/2012; 48(9):846-51. DOI: 10.1111/j.1440-1754.2012.02543.x
Source: PubMed

ABSTRACT Aim:  To review the use of antifungal chemoprophylaxis to prevent neonatal invasive fungal infections (IFI) in very low birthweight infants (VLBW <1500 g). Method:  Systematic review of randomised controlled trials. Results:  Nine trials were identified (2029 infants), with six comparing fluconazole with placebo/no treatment (840 infants), three comparing nystatin with placebo/no treatment (1200 infants) and two comparing fluconazole and nystatin (257 infants). Prophylactic fluconazole reduced the incidence of IFI in VLBW infants <1500 g to 5.1% compared with 16.0% in infants receiving placebo, relative risk (RR) = 0.36 (95% confidence interval 0.15-0.89). The mortality was 10.9% and 16.7%, respectively (RR 0.76, 0.54-1.08). Oral nystatin reduced the incidence of IFI in VLBW infants to 5.3% compared with 28.0% in infants receiving placebo (RR 0.16, 0.11-0.23). Mortality was 7.5% with nystatin and 10.9% with placebo (RR 0.86, 0.59-1.26). The incidence of IFI in studies comparing fluconazole and nystatin was 3.6% and 8.0%, respectively (RR 0.54, 0.19-1.56), and mortality was not significantly different: 4.6% versus 9.8% (RR 0.43, 0-4.31) Conclusions:  Prophylactic fluconazole and oral nystatin are both highly effective in preventing IFI in VLBW infants. Both agents are safe without significant toxicities. Antifungal prophylaxis should therefore be used in all VLBW infants. Given the paucity of data comparing fluconazole with nystatin, the choice of antifungal agent should be influenced by the incidence of IFI, local epidemiology and relative cost.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The antifungal ionophore nystatin dissipates the Na+ and K+ gradients across the cell membrane leading to cellular gain of Na+ and cellular loss of K+. The increase of cellular Na+ concentration may result in Ca2+ accumulation in exchange for Na+. Increase of cytosolic Ca2+ activity ([Ca2+]i) and loss of cellular K+ fosters apoptosis-like suicidal erythrocyte death or eryptosis, which is characterized by cell shrinkage and cell membrane scrambling leading to phosphatidylserine-exposure at the erythrocyte surface. The present study explored whether nystatin stimulates eryptosis.Cell volume was estimated from forward scatter, phosphatidylserine-exposure from annexin V binding and [Ca2+]i from Fluo3-fluorescence in flow cytometry.A 48-hr exposure to nystatin (15 μg/ml) was followed by a significant increase of [Ca2+]i, a significant increase of annexin V binding and a significant decrease of forward scatter. The annexin V binding following nystatin treatment was significantly blunted in the nominal absence of extracellular Ca2+. Partial replacement of extracellular Na+ with extracellular K+ blunted the nystatin-induced erythrocyte shrinkage but increased [Ca2+]i and annexin V binding.Nystatin triggers cell membrane scrambling, an effect at least partially due to entry of extracellular Ca2+.This article is protected by copyright. All rights reserved.
    Basic & Clinical Pharmacology & Toxicology 06/2014; 116(1). DOI:10.1111/bcpt.12279 · 2.29 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: PurposeThe prevalence of Candida infections has been rising with an increasingly aging population and a larger population of immunocompromised individuals. The use of probiotics may be an alternative approach to antifungal agents in the prevention and treatment of oral candidiasis. This study aimed to evaluate the short-term effect of probiotics in reducing the infection level of oral Candida in candidiasis-asymptomatic elderly denture wearers.Materials and Methods In a double-blind randomized study, 59 denture wearers harboring Candida spp. in the oral cavity with no clinical symptoms were allocated into two groups: probiotic and placebo. All patients were instructed to clean the denture daily. The probiotic group poured a capsule containing lyophilized Lactobacillus rhamnosus HS111, Lactobacillus acidophillus HS101, and Bifidobacterium bifidum daily on the palatal surface of the maxillary denture, whereas the placebo group was submitted to the same regimen using placebo capsules. Candida spp. infection levels were evaluated in palate mucosa samples obtained before and after a 5-week experimental period.ResultsAll patients harbored Candida in the palate mucosa at baseline. Fifty-five individuals completed the experimental period. The detection rate of Candida spp. was 92.0% in the placebo group after the experimental period, whereas it was reduced to 16.7% in the probiotic group. The reduction promoted by the probiotic regimen was independent of baseline characteristics such as Candida infection level and colonizing species, age of denture, and other variables.Conclusion The probiotic product was effective in reducing the colonization of the oral cavity with Candida in candidiasis-asymptomatic elderly denture wearers, suggesting that this multispecies probiotic could be used to prevent oral candidiasis. Clinical implications: Colonization of oral surfaces by Candida is considered a risk factor for invasive fungal infections. The use of a product with L. rhamnosus, L. acidophilus, and B. bifidum may represent an alternative treatment for reduction of Candida infections in elderly denture wearers.
    Journal of Prosthodontics 08/2014; 24(3). DOI:10.1111/jopr.12198 · 0.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fungal infections represent a serious problem in neonatal intensive care units (NICUs) worldwide. Preterm infants are a vulnerable population for major events and adverse sequelae from fungal sepsis. The primary fungus of concern in neonates is C. albicans, whose colonization is associated with devastating complication and high rate of mortality. Among the risk factors responsible for development of invasive fungal infections, previous mucosal and skin colonization are of primary importance. Fungal colonization in neonates may be secondary to either maternal transmission or nosocomial acquisition in the nursery. Antifungal prophylaxis is currently applied in different NICUs and in various patients groups with successful results. Prophylactic drugs can include oral nystatin and oral or intravenous fluconazole. To date, antifungal prophylaxis with fluconazole is the recommended approach for neonates lower than 1,000 g and/or 27 weeks' gestation or less, manly in NICUs with relatively high frequency of invasive candidiasis. First-line treatment of invasive fungal infections includes amphotericin B deoxycholate, lipid preparations of amphotericin B, fluconazole, or micafungin. However, data on pharmacokinetic, schedule treatment and appropriate dosage of antifungal agents in neonates, mainly in premature, are still limited. Future strategies to reduce neonatal morbidity and mortality derived from invasive fungal infections include new echinocandins not yet approved Proceedings of the 10 th International Workshop on Neonatology · Cagliari (Italy) · October 22